OSTEOPOROSIS: CELLULAR AND MOLECULAR MECHANISMS OF DEVELOPMENT AND TARGET MOLECULES IN SEARCH FOR NEW TREATMENTS OF THE DISEASE

Cover Page

Abstract


In a review of the literature reflects the modern understanding of the cellular-molecular mechanism development of osteoporosis. Reflects the importance of cytokine RANKL-RANK-OPG sistem and Wnt/β-catenin signaling pathway in the development process of osteoblasto- and osteoclastogenesis. Noting the key role in the process of bone formation a number of molecules of cell signaling pathway and their antagonists are of interest as a target molecule to search for new drugs treatment for osteoporosis.

About the authors

S Sagalovski

Email: sagalovsky@median-kliniken.de
Department of the Orthopoedic

References

  1. Baron R., Rawadi G. Targeting the Wnt/β-catenin pathway to regulate bone formation in the adult skeleton // Endocrinol. — 2007. — Vol. 148, N6. — P. 2635-2643.
  2. Brown J.P., Prince R.L., Deal C. et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized; blindet; phase 3 trial // J. Bone Miner. Res. — 2009. — Vol. 24, N1. — P. 153—161.
  3. Canalis E. Update in new anabolic therapies for osteoporosis // J. Clin. Endocriol. Metab. — 2010. — Vol. 95, N4. — P. 1496—1504.
  4. Choi S.C., Han J.K. Negative regulation of activin signal transduction // Vitam. Horm. — 2011. — Vol. 85, N2. — P. 79—104.
  5. Cummings S.R., San Martin J., McClung M.R. et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis // N. Engl. J. Med. — 2009. — Vol. 361, N8. — P. 756—765.
  6. Darnay B.G., Besse A., Poblenz A. et al. TRAFs in RANK signaling // Adv. Exp. Med.Biol. — 2007. — Vol. 597, N1. — P. 152—159.
  7. Dennison E.M. Osteoporosis in 2010: building bones and (safely) preventing breaks // Nat. Rev. Rheumatol. — 2011. — Vol. 7, N1. — P. 80—82.
  8. Dhanwal D.K., Dennison E.M., Harvey N.C. et al. Epidemiology of hip fracture: worldwide geographic variation // Indian J. Orthop. - 2011. — Vol. 45, N1. — P. 15—22.
  9. Eisman J.A., Bone H.G., Hosking D.J. et al. Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect // J. Bone Miner. Res. — 2011. — Vol. 26, N2. — P. 242—251.
  10. Fujisaki K., Tanabe N., Suzuki N. et al. Receptor activator of NF-kappaB ligand induced the expression of carbonic anhydrase II., cathepsin K., and matrix metalloproteinase-9 in osteoclast precursor RAW 264-7 cells // Life Sci. — 2007. — Vol. 30, N4. — P. 1311—1318.
  11. Gallagher J.C., Sai A.J. Molecular biology of bone remodeling: implications for new therapeutic targers for osteoporosis // Maturitas. - 2010. — Vol. 65, N4. — P. 301—307.
  12. Gruber R. Osteoporosetherapie und Frakturheilung // J. Für Mineralstoffwechsel. — 2010. — Bd.17, N1. — S. 6—10.
  13. Harvey N., Dennison E.M., Cooper C. Osteoporosis: impact on health and economics // Nat. Rev. Rheumatol. — 2010. — Vol. 6, N1. — P. 99—105.
  14. Häussler B., Gothe H., Gol D. et al. Epidemiology; treatment and costs of osteoporosis in Germany - the Bone EVA Study // Osteoporosis Int. — 2007. — Vol. 18, N1. — P. 77—84.
  15. Hoeppner L.H., Secreto F.J., Westendorf J.J. Wnt signaling as a therapeutic target for bone diseases // Expert. Opin. Ther. Targets. — 2009. — Vol. 13, N4. — P. 486—496.
  16. Hofbauer L., Rachner T. Die rolle des RANK/RANKL/OPGSignalwegs in Knochenstoffwechsel // Forbildung Osteologie. — Bd.3, N5. — S. 118—121.
  17. Imai Y., Kondoh S., Kouzmenko A., Kato S. Minireview: osteoprotective action of estrogenes is mediated by osteoclastic estrogen receptor-alpha // Mol. Endocrinol. — 2010. — Vol. 24, N5.— P. 877—885.
  18. IOF World Congress on Osteoporosis and 10th European Congress of Clinical and Economic aspects of Osteoporosis and Osteoarthritis // Osteoporosis Int. — 2010. — Vol. 21, N5. — S1—S6.
  19. Jabbar S., Drury J., Nordham J.N. et al. Osteoprotegerin, RANKL and bone turnoval in postmenopausal osteoporosis // J. Clin. Pathol. — 2011. — Vol. 64, N4. — P. 354—357.
  20. Jacob F. Neue targets in der Osteporosetherapie // Dtsch. Med. Wochenschr. — 2011. — Bd. 136, N17. — S. 898—903.
  21. Kendler D.L., Benhamou C.I., Brown J.P. et all. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy // J. Bone Miner. Res. — 2010. — Vol. 25, N1. — P. 72—81.
  22. Komori T. Regulation of osteoblast defferentiation by RUNX2 // Osteoimmunology. — 2010. — Vol. 658, N1. — P. 43—49.
  23. Kosteniuk P.J., Nguyen H.Q., McCabe J. et al. Denosumab, a fully human monoclonal antibody to RANKL., inhibits bone resorption and increases BMD in knok-in mice that express chimeric (murine/ human) RANKL // J. Bone Miner. Res. — 2009. — Vol. 24, N2. — P. 182—195.
  24. Kubota T., Michigami T., Ozono K. Wnt signaling in bone // Clin Pediatric Endocrinol. — 2010. — Vol. 19, N3. — P. 49—56.
  25. Leonard M., Lehmann M.K., White D.A., Wyman M. Denosumab: a new therapy for osteoporosis // Pharmacotherapy Update. — 2010. — Vol. 13, N1. — P. 10—19.
  26. Lesnyak O.M., Benevolenskaya L.I. Osteoporosis in Russian Federation: problems and perspectives // Rheumatol. Sci. Pract. — 2010. — Vol. 4, N1. — P. 14—18.
  27. Lewiecki E.M. Clinical use of denosumab for the treatment for postmenopausal osteoporosis // Cuur. Med. Res. Opin. — 2010. — Vol. 26, N2. — P. 2807—2812.
  28. Li X., Ominsky M.S., Warmington K.S. et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in rat model of postmenopausal osteoporosis // J. Bone Miner. Res. — 2009. — Vol. 24, N4. — P. 578—588.
  29. Lotinun S., Pearsall R.S., Horne W.C. et al. Activin receptor signaling: a potential therapeutic target for osteoporosis // Cuur. Mol. Pharmacol. — 2011. — Vol. 4, N3. — P. 105—115.
  30. Marie P.J., Kassem M. Osteoblasts in osteoporosis: past, emerging, and future anabolic targets // Eur. J. Endocrinol. — 2011. — Vol. 165, N1. — P. 1—10.
  31. Mason J.J., Williams B.O. SOST and DKK: antagonists of LRP family signaling as target for treating bone disease // J. Osteoporose. - 2010. — Vol. 2010: 460120.
  32. Matsumoto T., Abe M. TGF-β-related mechanisms of bone destruction in multiple myeloma // Bone. — 2011. — Vol. 48, N2. — P. 129—134.
  33. Mikosch P., Osteoporosetherapie mit Denosumab: 6-Jahres-Daten zu Knochendichte, Knochensatz und Verträglichkeit // J. für Mineralstoffwechsel. — 2011. — Bd.18, N1. — S. 56—57.
  34. Moen M.D., Keam S.J. Denosumab: a review of its use in the treatment of menopausal osteoporosis // Drug Aging. — 2011. — Vol. 28, N1. — P. 63—82.
  35. Moore W.J., Kern J.C., Bhat R. et al. Modulation of Wnt signaling through inhibition of secreted Frizzled-related protein 1 (sFRP-1). with N-substituted piperidinyl diphenylsulfonyl sulfonamides: part II // Bioorg. Med. Chem. — 2010. — Vol. 18, N1. — P. 190—204.
  36. Nagase Y., Tanaka S. Odanacatib (MK-0822). // Clin. Calcium. — 2011. — Vol. 21, N1 — P. 59—62.
  37. Ominsky M.S., Vlasserous F., Jolette J. et al. Two doses of sclerostin antibody in Cynomolgus monkeys increases bone formation, bone mineral density, and bone strength // J. Bone Miner. Res. — 2010. — Vol. 25, N5.— P. 948—959.
  38. Padhi D., Jang G., Stouch B., Fang L., Posvar E. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody // J. Bone Miner. Res. — 2011. — Vol. 26, N1. — P. 19—26.
  39. Pereira R.M.R., de Carvalho J.F., Canalis E. Glucocorticoid-induced osteoporosis in rheumatic diseases // Clinics. — 2010. — Vol. 65, N11. — P. 1197—1205.
  40. Perez-Castrillon J.L., Pinacho F., De Luis D. et al. Odanacatib, a new drug for the treatment of osteoporosis: review of the results in postmenopausal women // J. Osteoporosis. — 2010. — Vol. 2010: 401581.
  41. Pinzone J.J., Hall B.M., Thudi N.K. et al. The role of Dikkopf-1 in bone development, homeostasis, and disease // Blood. — 2009. — Vol. 119, N3. — P517—525.
  42. Raggatt L.J., Partridge N.C. Cellular and molecular mechanisms of bone remodeling // J. Biol. Chem. — 2010. — Vol. 285, N33. — P. 25103—25108.
  43. Rozhinskaya L.Y., Belaya Z.E. Treatment of osteoporosis: advances and perspectives // Profilac. Med. — 2009. — N6. — P. 21—26.
  44. Ruckle J., Jacobs M., Kramer W. et al. Single-dose, randomized, double-blind, placebo-controlled study of ACE-011 (ActRIIa-lgG1). in postmenopausal women // J. Bone Miner. Res. — 2009. — Vol. 24, N4. — P. 744—752.
  45. Ruschak A.M., Slassi M., Kay L.E., Schimmer A.D. Novel proteasome inhibitors to overcome bortezomib resistence // J. Natl. Cancer Invest. — 2011. — Vol. 103, N13. — P. 1007—1017.
  46. Sagalovsky S., Schönert M. RANKL-RANK-OPG system and bone remodeling: a new approach on the treatment of osteoporosis // Clin. Exptl. Pathol. — 2011. — Vol. 10, N2. — P. 146—153.
  47. Sarahrudi K., Mousavi M., Thomas A. et al. Elevated level of macrophage colony-stimulating factor in human fracture healing // J. Orthoped. Res. — 2010. — Vol. 28, N5. — P. 671—676.
  48. Schulze J., Seitz S., Saito H. et al. Negative regulation of bone formation by the transmembrane Wnt antagonist Kremen-2 // PloS ONE. — 2010. — Vol. 5, N4. — e10309.
  49. Silverman S.L. Sclerostin // J. Osteoporosis. — 2010. — Vol. 2010: 941419.
  50. Sugimoto T. Anti-RANKL monoclonal antibody denosumab (AMG 162). // Clin. Calcium. — 2011. — Vol. 21, N1. — P.46—51.
  51. Trivedi R., Goswami R., Chattopadhyay N. Investigational anabolic therapies for osteoporosis // Expt. Opin. Invest. Drugs. — 2010. — Vol. 19, N8. — P. 995—1005.
  52. Trouvin A.-P., Goeb V. Receptor activator of nuclear factor-kB ligand and osteoprotegerin: maintaining the balance to prevent bone loss // Clin. Intervent. Aging. — 2010. — Vol. 5, N4. — P. 345—354.
  53. Umland E.M. An update on osteoporosis epidemiology and bone physiology // Univer. Tennessee Adv. Stud. Pharmacy. — 2008. — Vol. 5, N7. — P.210—214.
  54. Valkenburg K.C., Graveel C.R., Zylstra-Diegel C.R. et al. Wnt/β-catenin signaling in normal and cancer stem cells // Cancers. — 2011. — Vol. 3, N2. — P. 2050—2079.
  55. Wadas T.J., Deng H., Sprague J.E. et al. Targeting the avb3 integrin for small-animal PET/CT of osteolytic bone metastases // J. Nucl. Med. — 2009. — Vol. 50, N11. — P1873—1880.
  56. Wagner D.O., Sieber C., Bhushan R. et al. BMPs: from bone to body morphogenetic proteins // Sci. Signal. — 2010. — Vol. 3, N107: mr 1.
  57. Wang L., Zhang X., Guo Y. et al. Involvement of BMPs/Smad signaling pathway in mechanical response in osteoblasts // Cell Physiol. Biochem. — 2010. — Vol. 26, N6. — P. 1093—1102.
  58. Yang R.S., Liu S.H. Current pharmacological approaches to prevent and treated postmenopausal osteoporosis // Recent Patents on Endocrine, Metab. Immune. Drug Discov. — 2009. — Vol. 3, N1. — P. 42—53.
  59. Zeng X., Huang H., Tamai K. et al. Inhibition of Wnt signaling: control Wnt coreceptor LRP 6 phosphorilation/activation via Frizzled, Disheveled and Axin function // Development. — 2008. — Vol. 135, N2. - P. 367—375.
  60. Zhao Q., Wang X., Liu Y. et al. NFATc1: functions in osteoporosis // Int. J. Biochem. Cell Biol. — 2010. — Vol. 42, N5. — P. 576—579.

Statistics

Views

Abstract - 2038

PDF (Russian) - 1069

Cited-By


PlumX

Dimensions


Copyright (c) 2012 Sagalovski S.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies